Current evidence does not suggest an additional increase in the risk of skin cancers in IBD patients treated with combination therapy involving TNFα inhibitors and a thiopurine or methotrexate when compared to the cancer risks associated with monotherapy using either agent. The gene discussed is TNF; the disease is cancer.